2.12MMarket Cap-0.06P/E (TTM)
0.8194High0.7511Low55.65KVolume0.8000Open0.8276Pre Close43.72KTurnover2.26%Turnover RatioLossP/E (Static)2.77MShares9.650052wk High0.32P/B1.88MFloat Cap0.751152wk Low--Dividend TTM2.46MShs Float594000.0000Historical High--Div YieldTTM8.25%Amplitude0.7511Historical Low0.7850Avg Price1Lot Size
Palisade Bio Stock Forum
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
Thursday, 20th February at 8:45 am
Company through its co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108
Ongoing progress of Palisade Bio's Phase 1a/b UC st...
2 MINUTES AGO, 8:45 AM EST
VIA GLOBENEWSWIRE
Data presented at the 2025 Crohn's and Colitis Congress
PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
Monday, 10th February at 8:45 am
Data presented at the 2025 Crohn's and Colitis Congress
PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure
Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts
Carlsbad, CA, Fe...
No comment yet